Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 8/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902877 | 0.82 | RAB9A (0.61) | RAB9AHSP90AA1PDPK1SYKSRC | |
| SCHEMBL2151538 | 0.75 | CCR1 (0.48) | RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL29476108 | 0.75 | CCR1 (0.48) | RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL4905135 | 0.74 | RAB9A (0.53) | RAB9AHSP90AA1PDPK1SYKSRC | |
| SCHEMBL2730329 | 0.74 | RAB9A (0.53) | RAB9AHSP90AA1PDPK1SYKSRC | |
| SCHEMBL9287533 | 0.74 | CCR1 (0.54) | RAB9AHSP90AA1PDPK1SYKSRC | |
| SCHEMBL30514101 | 0.72 | KDM4E (0.66) | RAB9ACYP1A2ALDH1A1 | |
| SCHEMBL2030486 | 0.72 | KDM4E (0.66) | RAB9ACYP1A2ALDH1A1 | |
| SCHEMBL20400251 | 0.72 | KDM4E (0.63) | RAB9AHSP90AA1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL3165466 | 0.72 | KDM4E (0.63) | RAB9AHSP90AA1CYP1A2ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| CN-103201261-A | Lactam derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-07-10 | — | — | CN | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| CN-1098263-C | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2003-01-08 | — | — | CN | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | RAB9A 1662/4885HSP90AA1 4387/4885PDPK1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.